# Lemonex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lemonex

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.lemonexbio.com
- Total disclosed funding: $27M
- Latest round: Series C (Apr 17, 2021)
- Investors on record: 16

## About

Based in Seoul, South Korea, and founded in 2013, Lemonex Inc. is a biotherapeutics biotechnology company that uses drug delivery and biosensor technologies to develop cancer immunotherapeutic, antibody therapeutics, and gene therapeutics. In 2019, the company received innovation award for small and middle size businesses. In 2020, the company received certificate of excellent technology evaluation. The company's current CEO is Cheolhee Won. 

The company uses its unique drug delivery and biosensor technologies to develop new drugs. Its drug delivery technology known as DegradaBALL is used in gene therapy, cancer immuno therapy, antibody therapy, and synthetic drugs. The company's biosensor technology known as PANGO is a molecular diagnostic and drug screening technology that are used in developing new virus therapeutics and anti-cancer vaccines. The company's pipeline for cancer immunotherapy & targeted cancer therapy includes BALLkine-2, LEM-S403, LEM-S404, and LEM-S405. Pipelines for intractable disease include LEM-S401 and LEM-S402.

## Funding rounds

- Series C, Apr 17, 2021, $11M — Industrial Bank of Korea, Smilegate Investment, IBK Capital, Quantum Ventures Korea, Meta Investment, KClavis Investment, Penture Invest, DB Securities
- Series C, Dec 24, 2020, $3.2M — L&S Venture Capital, Union Investment Partners
- Series B, Dec 6, 2018, $10M — Industrial Bank of Korea, KDB Capital, Shinhan Capital, Daekyo Investment, Union Investment Partners, Daegyeong Investment, T.S. Investment, DA Value Investment
- Series A, Feb 14, 2018, $2.4M — Daekyo Investment, L&S Venture Capital

## Investors

- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series A, Series B
- L&S Venture Capital (https://capitalatlas.ai/funds/l-s-venture-capital) — Series A, Series C
- Industrial Bank of Korea — Series B, Series C
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series B
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series B
- Union Investment Partners (https://capitalatlas.ai/funds/union-investment-partners) — Series B, Series C
- Daegyeong Investment (https://capitalatlas.ai/funds/daegyeong-investment) — Series B
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series B
- DA Value Investment (https://capitalatlas.ai/funds/da-value-investment) — Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series C
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series C
- Quantum Ventures Korea (https://capitalatlas.ai/funds/quantum-ventures-korea) — Series C
- Meta Investment (https://capitalatlas.ai/funds/meta-investment) — Series C
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series C
- Penture Invest (https://capitalatlas.ai/funds/penture-invest) — Series C
- DB Securities (https://capitalatlas.ai/funds/db-securities) — Series C